The global human insulin market is experiencing steady growth as the demand for effective diabetes management continues to increase. The human insulin market share is influenced by the growing adoption of insulin analogues, expanding access to diabetes treatment, and product innovation. Increasing investments in insulin manufacturing and distribution are also shaping the competitive landscape.
According to Fortune Business Insights, the global human insulin market size was valued at USD 20.22 billion in 2025 and is projected to grow from USD 20.79 billion in 2026 to USD 26.93 billion by 2034, exhibiting a CAGR of 3.29% during the forecast period (2026–2034). North America dominated the human insulin market with a market share of 45.57% in 2025.
Human insulin is a medication used to regulate blood glucose levels in individuals with diabetes. It helps the body manage glucose and maintain glycemic control when natural insulin production is insufficient or when the body cannot use insulin effectively. The market includes traditional human insulin and insulin analogues, which are developed to provide different action profiles and support varied treatment requirements. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.
Leading companies in the human insulin market are focusing on research and development, manufacturing capabilities, product launches, and strategic collaborations. Key companies include:
Increasing prevalence of diabetes: The rising number of people living with diabetes is a major factor supporting demand for human insulin. Insulin is essential for individuals with type 1 diabetes and is also prescribed to certain patients with type 2 diabetes when other treatment approaches do not provide adequate blood glucose control. Increasing awareness, diagnosis, and long-term disease management requirements are supporting the adoption of insulin products.
Product innovation and new insulin launches: Manufacturers are introducing new insulin formulations and delivery options to address different treatment requirements. Insulin analogues offer varied onset and duration profiles, supporting more flexible treatment approaches. Product launches, biosimilar development, and improvements in insulin delivery formats are contributing to market development.
Restraint – Limited reimbursement and affordability: The cost of insulin treatment and differences in healthcare reimbursement systems can affect access, particularly in emerging and underdeveloped markets. In regions where patients rely heavily on out-of-pocket spending, affordability can restrict treatment adoption. Limited insurance coverage and gaps in healthcare financing may further constrain market growth.
Restraint – Low diagnosis rates: Undiagnosed diabetes remains a challenge in several countries. Individuals who are unaware of their condition may not receive timely treatment, limiting the potential demand for insulin products. Improvements in screening, diagnosis, and healthcare access are important for addressing this gap.